MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin

Early Phase 1
Not yet recruiting
Conditions
Non-Alcoholic Fatty Liver Disease
Hepatic Steato-Fibrosis
Interventions
First Posted Date
2024-04-18
Last Posted Date
2024-08-09
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
60
Registration Number
NCT06373523
Locations
🇮🇳

PGIMER, Chandigarh, Punjab, India

Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage

Not Applicable
Recruiting
Conditions
Intracerebral Hemorrhage
Low T3 Syndrome
Neurocritical Care
Hormone Replacement Therapy
Interventions
First Posted Date
2024-04-09
Last Posted Date
2024-04-09
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
100
Registration Number
NCT06353555
Locations
🇨🇳

Peking union medical college hospital, Beijing, Beijing, China

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Phase 2
Recruiting
Conditions
Hypothyroidism
Interventions
First Posted Date
2024-04-03
Last Posted Date
2025-04-09
Lead Sponsor
AbbVie
Target Recruit Count
2800
Registration Number
NCT06345339
Locations
🇺🇸

St. Louis University /ID# 262375, Saint Louis, Missouri, United States

🇺🇸

Diabetes and Endocrinology Specialists /ID# 259068, Chesterfield, Missouri, United States

🇺🇸

Omega Clinical Research /ID# 260162, Metairie, Louisiana, United States

and more 134 locations

Neurodevelopmental Impact of Treatment in Hypothyroxinaemia of Prematurity.

Completed
Conditions
Transient Hypothyroxinemia of Prematurity
Interventions
Other: THOP without treatment
Other: NoTHOP
First Posted Date
2024-04-03
Last Posted Date
2024-04-03
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
373
Registration Number
NCT06346236
Locations
🇫🇷

CHU Saint EtienneHopital, Saint-Étienne, France

🇫🇷

HFME, Bron, France

🇫🇷

CHU Grenoble, Grenoble, France

Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism

Phase 3
Completed
Conditions
Hypothyroidism Primary
Lipid Disorder
Dyslipidemias
Interventions
First Posted Date
2024-02-23
Last Posted Date
2025-03-11
Lead Sponsor
King Edward Medical University
Target Recruit Count
62
Registration Number
NCT06276205
Locations
🇵🇰

King Edward Medical University, Lahore, Punjab, Pakistan

Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit

Recruiting
Conditions
Thyroid; Functional Disturbance
Interventions
First Posted Date
2023-12-04
Last Posted Date
2025-05-11
Lead Sponsor
Meir Medical Center
Target Recruit Count
350
Registration Number
NCT06154382
Locations
🇮🇱

Meir Medical Center, Kfar Saba, Israel

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Phase 2
Recruiting
Conditions
Thyroid Cancer
Surgery
Recurrence
Interventions
First Posted Date
2023-10-17
Last Posted Date
2023-10-17
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
140
Registration Number
NCT06087068
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

Dosing of LT4 in Older Individuals

Phase 4
Recruiting
Conditions
Hypothyroidism
Interventions
First Posted Date
2023-10-10
Last Posted Date
2025-02-28
Lead Sponsor
University of Pennsylvania
Target Recruit Count
228
Registration Number
NCT06073665
Locations
🇺🇸

Penn Medicine, Smilow Translational Research Center, Philadelphia, Pennsylvania, United States

Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism

Not Applicable
Recruiting
Conditions
Female Infertility
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Subclinical Hypothyroidism
Interventions
First Posted Date
2023-09-18
Last Posted Date
2024-06-04
Lead Sponsor
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy
Target Recruit Count
200
Registration Number
NCT06041204
Locations
🇪🇬

Al-Hussein University Hospital, Cairo, Egypt

Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women

Phase 3
Completed
Conditions
Thyroid Diseases
Recurrent Early Pregnancy Loss
Interventions
First Posted Date
2023-09-14
Last Posted Date
2023-09-14
Lead Sponsor
Al-Kindy College of Medicine
Target Recruit Count
77
Registration Number
NCT06036576
Locations
🇮🇶

AL-Elwiyah Maternity Teaching Hospital, Baghdad, Iraq

© Copyright 2025. All Rights Reserved by MedPath